ThermoGenesis Holdings is a small medical device company transitioning into a contract development and manufacturing organization (CDMO) for cell and gene therapy companies. Its legacy business centers on two products for the cord blood banking industry: the AXP II Automated Cell Separation System, which isolates stem cells from umbilical cord blood, and the BioArchive Automated Cryopreservation System, a robotic liquid nitrogen storage system. ThermoGenesis claims BioArchive stores close to 90% of all U.S. FDA-approved clinical-grade cord blood units. The legacy business generates revenue through one-time capital equipment sales and recurring single-use AXP processing kit disposables, the latter being the primary ongoing revenue driver. ThermoGenesis also sells X-Series cell processing products globally through an exclusive distribution agreement with Corning. The emerging CDMO business is built around a new 35,500 sq. ft. facility in Sacramento housing 12 leasable ISO 7 cGMP cleanroom suites, targeted at small to mid-sized biotech companies developing cell and gene therapies. ThermoGenesis plans to generate revenue by leasing suites and, longer term, offering full-service manufacturing including process development, quality systems design, and regulatory support. A key tool in this effort is the CAR-TXpress platform, a proprietary semi-automated CAR-T manufacturing system that ThermoGenesis claims can reduce manufacturing costs by up to 50%. Management's thesis is that CDMO capacity for cell therapies is severely constrained, creating a near-term opportunity for a facility with available, compliant cleanroom space and relevant manufacturing expertise.